Heron Therapeutics (HRTX) EPS (Basic) Growth (1y) (2012 - 2026)
Powered by 
Analysis
Heron Therapeutics (HRTX) EPS (Basic) Growth (1y) (2012 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 65.24% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -636.10% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 7.74% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | -4.72% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 87.85% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 7.59% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 322.67% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -84.77% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 96.41% |
| 10 | Heron Therapeutics | 64.55 Mn | 21.89 Mn | 26.09 Mn | -0.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.92% |
| Mar 31, 2026 | -223.00% |
| Dec 31, 2025 | -76.25% |
| Sep 30, 2025 | 16.75% |
| Jun 30, 2025 | 74.86% |
| Mar 31, 2025 | 164.25% |
| Dec 31, 2024 | 201.45% |
| Sep 30, 2024 | 83.21% |
| Jun 30, 2024 | 88.05% |
| Mar 31, 2024 | 88.50% |
| Dec 31, 2023 | 70.97% |
| Sep 30, 2023 | 54.19% |
| Jun 30, 2023 | 26.70% |
| Mar 31, 2023 | 55.04% |
| Dec 31, 2022 | 68.05% |
| Sep 30, 2022 | 26.11% |
| Jun 30, 2022 | 21.40% |
| Mar 31, 2022 | -7.77% |
| Dec 31, 2021 | 16.18% |
| Sep 30, 2021 | 21.53% |